Designer natriuretic peptides: A vision for the future of heart failure therapeutics

Canadian Journal of Physiology and Pharmacology

Volumn 89, Issue 8, 2011, Pages 593-601

  Zakeri, Rosita ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

CD NP; Chimerics; CU NP; Cyclic GMP; Heart failure; Natriuretic peptides

Indexed keywords

CYCLIC GMP; ENDOTHELIN 1; GUANYLATE CYCLASE; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; DIURESIS; HEART FAILURE; HYPERTENSION; HYPOTENSION; IN VIVO STUDY; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL;

ANIMALS; DESIGNER DRUGS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES;

EID: 79961191363     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/y11-048     Document Type: Article

References (50)

1. Abbey, S.E., and Potter, L.R. 2002. Vasopressin-dependent inhibition of the C-type natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular calcium concentrations. J. Biol. Chem. 277 (45): 42423-42430. doi:10.1074/jbc.M206686200. PMID: 12196532.
2. Abraham, W.T., Adams, K.F., Fonarow, G.C., Costanzo, M.R., Berkowitz, R.L., LeJemtel, T.H., et al. ADHERE Scientific Advisory Committee and InvestigatorsADHERE Study Group. 2005. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol. 46(1): 57-64. doi:10. 1016/j.jacc.2005.03.051. PMID:15992636.
3. Brown, L.A., Nunez, D.J., and Wilkins, M.R. 1993. Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat. J. Clin. Invest. 92(6): 2702-2712. doi:10.1172/JCI116887. PMID:7902846.
4. Chen, H.H., Sundt, T.M., Cook, D.J., Heublein, D.M., and Burnett, J. C., Jr. 2007. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopul-monary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation, 116(11 Suppl.): I134-I138. doi:10.1161/ CIRCULATIONAHA.106.697250. PMID:17846293.
5. Chen, H.H., Cataliotti, A., Schirger, J.A., Martin, F.L., Harstad, L.K., and Burnett, J.C., Jr. 2009a. Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. J. Am. Coll. Cardiol. 53(15): 1302-1308. doi:10.1016/j.jacc.2009.01.030. PMID:19358945.
6. Chen, H.H., Martin, F.L., Gibbons, R.J., Schirger, J.A., Wright, R.S., Schears, R.M., et al. 2009b. Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart, 95(16): 1315-1319. doi:10.1136/hrt.2008.153916. PMID: 19447837.
7. Clavell, A.L., Stingo, A.J., Wei, C.M., Heublein, D.M., and Burnett, J.C., Jr. 1993. C-type natriuretic peptide: a selective cardiovascular peptide. Am. J. Physiol. 264(2 Pt 2): R290-R295. PMID:8383462.
8. Cody, R.J., Atlas, S.A., Laragh, J.H., Kubo, S.H., Covit, A.B., Ryman, K.S., et al. 1986. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Invest. 78(5): 1362-1374. doi:10.1172/JCI112723. PMID: 2945832.
9. Dickey, D.M., Burnett, J.C., Jr, and Potter, L.R. 2008. Novel bifunctional natriuretic peptides as potential therapeutics. J. Biol. Chem. 283(50): 35003-35009. doi:10.1074/jbc.M804538200. PMID:18940797.
10. Doyle, D.D., Upshaw-Earley, J., Bell, E.L., and Palfrey, H.C. 2002. Natriuretic peptide receptor-B in adult rat ventricle is predominantly confined to the nonmyocyte population. Am. J. Physiol. Heart Circ. Physiol. 282(6): H2117-H2123. PMID:12003819.
11. Dries, D.L., Ky, B., Wu, A.H., Rame, J.E., Putt, M.E., and Cappola, T.P. 2010. Simultaneous assessment of unprocessed ProBNP1- 108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure. Circ. Heart Fail. 3 (2): 220-227. doi:10.1161/CIRCHEARTFAILURE.109.903153. PMID:20107190.
12. Edwards, B.S., Schwab, T.R., Zimmerman, R.S., Heublein, D.M., Jiang, N.S., and Burnett, J.C., Jr. 1986. Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension. Circ. Res. 59(6): 663-667. PMID: 2949886.
13. Edwards, B.S., Zimmerman, R.S., Schwab, T.R., Heublein, D.M., and Burnett, J.C., Jr. 1988. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ. Res. 62(2): 191-195. PMID:2962782.
14. + exchanger-1 (NHE-1) inhibition. Can. J. Physiol. Pharmacol. 85(3-4): 301- 310. doi:10.1139/Y06-072. PMID:17612638.
15. Fifer, M.A., Molina, C.R., Quiroz, A.C., Giles, T.D., Herrmann, H. C., De Scheerder, I.R., et al. 1990. Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. Am. J. Cardiol. 65(3): 211-216. doi:10.1016/0002-9149(90)90087-H. PMID:2136969.
16. Hawkridge, A.M., Heublein, D.M., Bergen, H.R., Cataliotti, A., Burnett, J.C., and Muddiman, D.C. 2005. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc. Natl. Acad. Sci. U.S.A. 102(48): 17442-17447. doi:10.1073/pnas. 0508782102. PMID:16293687.
17. He, J., Chen, Y., Huang, Y., Yao, F., Wu, Z., Chen, S., et al. 2009. Effect of long-term B-type natriuretic peptide treatment on left ventricular remodeling and function after myocardial infarction in rats. Eur. J. Pharmacol. 602(1): 132-137. doi:10.1016/j.ejphar. 2008.10.064. PMID:19027731.
18. Hernandez, A. 2010. Acute study of clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). 2010 clinical trial/clinical science abstracts: Abstract No. 21828. Circulation, 122(21): 2215-2226. doi:10.1161/CIR. 0b013e318200c0b5.
19. Heublein, D.M., Huntley, B.K., Boerrigter, G., Cataliotti, A., Sandberg, S.M., Redfield, M.M., and Burnett, J.C., Jr. 2007. Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension, 49(5): 1114-1119. doi:10.1161/ HYPERTENSIONAHA.106.081083. PMID:17372040.
20. Hirsch, J.R., Meyer, M., and Forssmann, W.G. 2006. ANP and urodilatin: who is who in the kidney. Eur. J. Med. Res. 11(10): 447-454. PMID:17107879.
21. Horio, T., Tokudome, T., Maki, T., Yoshihara, F., Suga, S., Nishikimi, T., et al. 2003. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology, 144(6): 2279-2284. doi:10. 1210/en.2003-0128. PMID:12746286.
22. Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G. S., Ganiats, T.G., et al. American College of Cardiology Foundation/American Heart Association. 2009. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53(15): e1-e90. doi:10. 1016/j.jacc.2008.11.013. PMID:19358937.
23. Inoue, K., Naruse, K., Yamagami, S., Mitani, H., Suzuki, N., and Takei, Y. 2003. Four functionally distinct C-type natriuretic peptides found in fish reveal evolutionary history of the natriuretic peptide system. Proc. Natl. Acad. Sci. U.S.A. 100(17): 10079- 10084. doi:10.1073/pnas.1632368100. PMID:12893874.
24. Kangawa, K., Fukuda, A., Minamino, N., and Matsuo, H. 1984. Purification and complete amino acid sequence of beta-rat atrial natriuretic polypeptide (-rANP) of 5,000 daltons. Biochem. Biophys. Res. Commun. 119(3): 933-940. doi:10.1016/0006-291X(84)90863-5. PMID:6231929.
25. Karmazyn, M., Kilić, A., and Javadov, S. 2008. The role of NHE-1 in myocardial hypertrophy and remodelling. J. Mol. Cell. Cardiol. 44(4): 647-653. doi:10.1016/j.yjmcc.2008.01.005. PMID: 18329039.
26. Kasama, S., Furuya, M., Toyama, T., Ichikawa, S., and Kurabayashi, M. 2008. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur. Heart J. 29(12): 1485-1494. doi:10.1093/eurheartj/ehn206. PMID: 18490430.
27. Kilić, A., Rajapurohitam, V., Sandberg, S.M., Zeidan, A., Hunter, J. C., Said Faruq, N., et al. 2010. A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway. Cardiovasc. Res. 88(3): 434-442. doi:10. 1093/cvr/cvq254. PMID:20679416.
28. Kociol, R.D., Hammill, B.G., Fonarow, G.C., Klaskala, W., Mills, R. M., Hernandez, A.F., and Curtis, L.H. 2010. Generalizability and longitudinal outcomes of a national heart failure clinical registry: comparison of acute decompensated heart failure national registry (ADHERE) and non-ADHERE Medicare beneficiaries. Am. Heart J. 160(5): 885-892. doi:10.1016/j.ahj.2010.07.020. PMID: 21095276.
29. Lee, C.Y., and Burnett, J.C., Jr. 2007. Discovery of a novel synthetic natriuretic peptide, CU-NP. J. Card. Fail. 13(6 Suppl. 2): S74. [Abstract.] doi:10.1016/j.cardfail.2007.06.307.
30. Lee, C.Y., Huntley, B.K., Sandberg, S.M., Chen, H.H., and Burnett, J.C., Jr. 2008a. A novel designer natriuretic peptide, CU-NP, in human aortic endothelial cells: evidence for NPR-B involvement in cyclic GMP response. Can. J. Clin. Pharmacol. 15: e517. [Abstract.]
31. Lee, C.Y., Chen, H.H., Sandberg, S.M., Harty, G.M., and Burnett, J. C., Jr. 2008b. Renal mechanisms of action of a novel designer natriuretic peptide. J. Card. Fail. 14(6 Suppl. 1): S79-S80. doi:10. 1016/j.cardfail.2008.06.440.
32. Lee, C.Y., Chen, H.H., Lisy, O., Swan, S., Cannon, C., Lieu, H.D., and Burnett, J.C., Jr. 2009. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J. Clin. Pharmacol. 49(6): 668-673. doi:10.1177/ 0091270009336233. PMID:19395584.
33. Liang, F., O'Rear, J., Schellenberger, U., Tai, L., Lasecki, M., Schreiner, G.F., et al. 2007. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J. Am. Coll. Cardiol. 49(10): 1071- 1078. doi:10.1016/j.jacc.2006.10.063. PMID:17349887.
34. Lieu, H., Goldsmith, S., Neutal, J., Massie, B., and Burnett, J. 2009. Initial observations of intravenous CD-NP, chimeric natriuretic peptide, on renal functions in chronic heart failure patients. J. Card. Fail. 15(6): S77. doi:10.1016/j.cardfail.2009.06.180.
35. Lisy, O., Huntley, B.K., McCormick, D.J., Kurlansky, P.A., and Burnett, J.C., Jr. 2008. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J. Am. Coll. Cardiol. 52(1): 60-68. doi:10.1016/j.jacc.2008.02.077. PMID:18582636.
36. Lisy, O., Chen, H.H., and Burnett, J.C., Jr. 2009. Cardiorenal actions of new designer natriuretic peptide CD-NP in experimental heart failure. J. Am. Coll. Cardiol. 53: A149.
37. Martin, F.L., Sangaralingham, S.J., McKie, P.M., Huntley, B.K., Harders, G.E., Chen, H.H., and Burnett, J.C. 2009. Prevention of cardiorenal fibrosis and suppression of proteinuria and aldosterone activation following experimental myocardial infarction with the novel natriuretic peptide CD-NP. J. Card. Fail. 15(6): S3. doi:10. 1016/j.cardfail.2009.06.421.
38. Niederkofler, E.E., Kiernan, U.A., O'Rear, J., Menon, S., Saghir, S., Protter, A.A., et al. 2008. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ. Heart Fail. 1(4): 258-264. doi:10.1161/ CIRCHEARTFAILURE.108.790774. PMID:19808300.
39. Potter, L.R., Abbey-Hosch, S., and Dickey, D.M. 2006. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 27(1): 47-72. doi:10. 1210/er.2005-0014. PMID:16291870.
40. Publication Committee for the VMAC Investigators. 2002. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, 287(12): 1531-1540. doi:10.1001/jama.287.12.1531. PMID:11911755.
41. Riter, H.G., Redfield, M.M., Burnett, J.C., and Chen, H.H. 2006. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J. Am. Coll. Cardiol. 47(11): 2334-2335. doi:10.1016/j.jacc.2006.03.013. PMID:16750705.
42. Sackner-Bernstein, J.D., Kowalski, M., Fox, M., and Aaronson, K. 2005a. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA, 293(15): 1900-1905. doi:10.1001/jama. 293.15.1900. PMID:15840865.
43. Sackner-Bernstein, J.D., Skopicki, H.A., and Aaronson, K.D. 2005b. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation, 111(12): 1487-1491. doi:10.1161/01.CIR.0000159340.93220.E4. PMID:15781736.
44. Schweitz, H., Vigne, P., Moinier, D., Frelin, C., and Lazdunski, M. 1992. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. 267(20): 13928-13932. PMID:1352773.
45. Stingo, A.J., Clavell, A.L., Aarhus, L.L., and Burnett, J.C., Jr. 1992. Cardiovascular and renal actions of C-type natriuretic peptide. Am. J. Physiol. 262(1 Pt 2): H308-H312. PMID:1310235.
46. Tokudome, T., Horio, T., Soeki, T., Mori, K., Kishimoto, I., Suga, S., et al. 2004. Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways. Endocrinology, 145(5): 2131-2140. doi:10.1210/en.2003-1260. PMID:14749356.
47. Wang, Y., de Waard, M.C., Sterner-Kock, A., Stepan, H., Schultheiss, H.P., Duncker, D.J., and Walther, T. 2007. Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur. J. Heart Fail. 9(6-7): 548-557. doi:10.1016/j.ejheart.2007.02. 006. PMID:17407830.
48. Weder, A.B., Sekkarie, M.A., Takiyyuddin, M., Schork, N.J., and Julius, S. 1987. Antihypertensive and hypotensive effects of atrial natriuretic factor in men. Hypertension, 10(6): 582-589. PMID: 2961688.
49. Wei, C.M., Aarhus, L.L., Miller, V.M., and Burnett, J.C., Jr. 1993. Action of C-type natriuretic peptide in isolated canine arteries and veins. Am. J. Physiol. 264(1 Pt 2): H71-H73. PMID:8430863.
50. Yandle, T.G. 1994. Biochemistry of natriuretic peptides. J. Intern. Med. 235(6): 561-576. doi:10.1111/j.1365-2796.1994.tb01263.x. PMID:8207362.